Detoxification and Drainage Eliminating toxins from the body By Bruce H. Shelton, MD, MD(h), DiHom

There are very few patients who don’t need detoxification and drainage intervention at all. Furthermore, each patient’s status is unique, so in designing a treatment plan, it is important to strike a balance between the patient’s previous exposure (toxic load) and the organism’s ability to detoxify (regulation ability).

For this purpose, patients are generally divided into two groups. Group 1 includes patients with mild to moderate toxicity. In general, these are patients with mild symptoms and exposure. They elect to do a general cleansing or have milder diseases such as headaches, acne, etc. Group 2 includes patients with severe toxicity (known exposure) as well as patients with severe diseases such as cancer, autoimmune diseases, etc. These patients’ regulation ability is reduced. Group 2 also includes former drug addicts as well as patients who have received chemotherapy.

Due to their advanced toxicity, Group 2 patients need advanced supportive detoxification that prepares the organs of detoxification and elimination for the drainage phase (accomplished primarily through Lymphomyosot, a component of the Detox-Kit). The advanced organ support is thus more organotropic in character, whereas the basic detoxification and drainage is more functiotropic. In general, advanced organ support is administered for six weeks, followed by use of the Detox-Kit. In most cases, tissues will still need to be drained of residual toxins, so the use of Lymphomyosot alone is advised for several months longer (for protocols, see BT Winter 2007).

Special case 1:

Patients with inflammatory skin disease, such as eczema or psoriasis. The skin, classically called the “mirror of the soul,” is also a mirror of the liver and the gut. In cases of skin disease, it is essential to remember that the P450-containing system in the skin is the same as that in the liver and in the gut. Psoriasis patients in particular need bowel cleansing, which should be part of the initial advanced organ support. Thus Mucosa compositum and Cutis Compositum play a special role in these patients, although functiotropic medications such as Nux vomica-Homaccord, Berberis-Homaccord, and Lymphomyosot, along with Hepeel, are the mainstays in the treatment of skin disease. Patients with inflammatory skin disease are at high risk of flare-ups if toxin drainage is initiated before the liver and gut are ready to cope with the load. These patients need to be treated with care even though they may not seem very ill. In some cases, flare-ups will simply mean that patients need higher doses of cortisone, but in other cases hospitalization may become necessary if skin sloughing is severe.

Patients with eczema are in a Th2 rigidity state, so they should first undergo several weeks of initial immunomodulation to get the disease under control, followed by advanced organ support, before the drainage period is initiated. Engystol is the medication of choice together with the appropriate suis-organ preparation, in this case Cutis compositum. By contrast, patients with psoriasis are in a Th1 state, so they should be treated with Traumeel oral ampoules and Cutis compositum. In both cases, it is preferable to add the catalysts during the drainage phase rather than during advanced organ support (see protocol in Table 1).

Table 1: Protocol for inflammatory skin disease

Disease-Specific Treatment

For Th1 rigidity: Traumeel and Cutis compositum
For Th2 rigidity: Engystol and Cutis compositum
Schwef-Heel

---

Weeks 1–4 (or even longer in severe cases)

Organ/System	Treatment
Liver	—
Urinary tract/Kidney	—
Lymph	—
Skin	Cutis compositum
Gut	Mucosa compositum
Connective tissue	—

Note:
Due to the high incidence of leaky gut in inflammatory skin diseases, initial treatment of the gut and immune system is paramount. The suis organs induce Th3 cells and thus immunotolerance to the corresponding organs.

Dosage:

• Ampoules: In general, 3–1 times weekly, 1 ampoule i.m., s.c., i.d.
• Drops: In general, 10 drops 3 times daily

---

Advanced Organ Support

Duration: 6 weeks

Organ/System	Primary Treatment	Alternative Products
Liver	Hepar compositum	Hepeel
Urinary tract/Kidney	Solidago compositum	Reneel
Lymph	—	Galium-Heel / Lymphomyosot
Skin	Cutis compositum	Schwef-Heel
Gut	Mucosa compositum	Nux vomica-Homaccord
Connective tissue	Thyreoidea compositum	Pulsatilla compositum

---

Basic Detoxification and Drainage

Organ/System	Detox Treatment	Cellular Detox (Add)
Liver	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Urinary tract/Kidney	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Lymph	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Skin	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Gut	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Connective tissue	Detox-Kit	Coenzyme compositum / Ubichinon compositum

Note:
Because Schwef-Heel is a potency chord, it does not cause aggravation to the extent classically ascribed to sulfur-containing medications. Adjuvant use of probiotics throughout the treatment should be considered.

Dosage:

• Ampoules: In general, 3–1 times weekly, 1 ampoule i.m., s.c., i.d.
• Drops: In general, 10 drops 3 times daily

---

Practical Protocols

Chronic fatigue syndrome is a complex and highly debilitating disorder characterized by chronic mental and physical exhaustion. It occurs more often, but not exclusively, in women.

Special case 2: Patients with chronic fatigue syndrome.

All patients with chronic fatigue syndrome have some form of toxicity. Some of these patients present primarily with symptoms of intoxication and have a history of toxic exposure, often temporally related to the onset of the syndrome.

Due to general immune imbalance (Th2 rigidity) and mitochondrial impairment in these patients, advanced organ support is essential, but even before that, support for the mucous membranes, the immune system, and the neuroendocrine system is helpful. This is best done with a combination of Mucosa compositum and Tonsilla compositum. After two weeks, advanced organ support can begin, followed by the drainage phase. If relapse occurs during the drainage phase, advanced organ support should be resumed for at least another six weeks (see protocol in Table 2).

Table 2: Protocol for chronic fatigue syndrome

Disease-Specific Treatment: Aletris-Heel

Followed by detoxification therapy

---

Weeks 1–2

Organ/System	Treatment
Liver	—
Urinary tract/Kidney	—
Lymph	Tonsilla compositum
Gut	Mucosa compositum
Connective tissue	—

---

Weeks 3–8: Advanced Organ Support

Organ/System	Primary Treatment	Alternative Products
Liver	Hepar compositum	Hepeel
Urinary tract/Kidney	Solidago compositum	Reneel
Lymph	Tonsilla compositum	Galium-Heel
Gut	Mucosa compositum	Nux vomica-Homaccord
Connective tissue	Thyreoidea compositum	Pulsatilla compositum

---

Weeks 9–20: Basic Detoxification and Drainage

Organ/System	Detox Treatment	Cellular Detox (Add)
Liver	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Urinary tract/Kidney	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Lymph	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Gut	Detox-Kit	Coenzyme compositum / Ubichinon compositum
Connective tissue	Detox-Kit	Coenzyme compositum / Ubichinon compositum

---

Note:
These patients need very gradual treatment. Because they often have multiple chemical sensitivities, it is advisable to first restore the integrity of the gut lining while administering Tonsilla compositum to support the adrenals and the hypothalamus. This also supports the immune system.

Dosage:

• Ampoules: In general, 3–1 times weekly, 1 ampoule i.m., s.c., i.d.
• Drops: In general, 10 drops 3 times daily